Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies

[Image: see text] Inhibition of the androgen receptor (AR) is the mainstay treatment for advanced prostate cancer. Ralaniten (formally EPI-002) prevents AR transcriptional activity by binding to its N-terminal domain (NTD) which is essential for transcriptional activity. Ralaniten acetate (EPI-506)...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:ACS Pharmacol Transl Sci
Auteurs principaux: Obst, Jon K., Wang, Jun, Jian, Kunzhong, Williams, David E., Tien, Amy H., Mawji, Nasrin, Tam, Teresa, Yang, Yu Chi, Andersen, Raymond J., Chi, Kim N., Montgomery, Bruce, Sadar, Marianne D.
Format: Artigo
Langue:Inglês
Publié: American Chemical Society 2019
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7088963/
https://ncbi.nlm.nih.gov/pubmed/32259077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsptsci.9b00065
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires